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ORIGINAL ARTICLES
Results of Pancreaticoduodenectomy in Patients With
Periampullary Adenocarcinoma
Perineural Growth More Important Prognostic Factor Than
Tumor Localization
Margijske H. G. van Roest, MD,* Annette S. H. Gouw, MD, PhD,† Paul M. J. G. Peeters, MD, PhD,*
Robert J. Porte, MD, PhD,* Maarten J. H. Slooff, MD, PhD,* Vaclav Fidler, PhD,‡
and Koert P. de Jong, MD, PhD*
Objective: To study the impact of perineural growth as a prognostic
factor in periampullary adenocarcinoma (pancreatic head, ampulla
of Vater, distal bile duct, and duodenal carcinoma).
Summary Background Data: Pancreatic head carcinoma is con-
sidered to have the worst prognosis of the periampullary carcinomas.
Several other prognostic factors for periampullary tumors have been
identified, eg, lymph node status, free resection margins, tumor size
and differentiation, and vascular invasion. The impact of perineural
growth as a prognostic factor in relation to the site of origin of
periampullary carcinomas is unknown.
Methods: Data of 205 patients with periampullary carcinomas were
retrieved from our prospective database. Pancreaticoduodenectomy
was performed in 121 patients. Their clinicopathological data were
reviewed and analyzed in a multivariate analysis.
Results: Perineural growth was present in 49% of the cases (37 of
the 51 patients with pancreatic head carcinoma; 7 of the 30 patients
with ampulla of Vater carcinoma; 7 of the 19 with distal bile duct
carcinoma; and 8 of the 21 with duodenal carcinoma). Overall
5-year survival was 32.6% with a median survival of 20.7 months.
Median survival in tumors with perineural growth was 13.1 months
compared with 36.0 months in tumors without perineural growth
(P 0.0001) Using multivariate analysis, the following unfavorable
prognostic factors were identified: perineural growth (RR  2.90,
95% CI 1.62–5.22), nonradical resection (RR  2.28, 95% CI
1.19–4.36), positive lymph nodes (RR  1.96, 95% CI 1.11–3.45),
and angioinvasion (RR  1.79, 95% CI 1.05–3.06). Portal or
superior mesenteric vein reconstruction and tumor localization were
not of statistical significance.
Conclusion: Perineural growth is a more important risk factor for
survival than the primary site of periampullary carcinomas.
(Ann Surg 2008;248: 97–103)
Periampullary tumors encompass carcinomas of the pan-creatic head, distal bile duct, duodenum, and ampulla
of Vater.1 In general, pancreatic head carcinoma is con-
sidered to have the worst prognosis among these tumor
types.2–9 Especially ampullary carcinomas seem to have a
better prognosis, which might be related to the fact that
jaundice is an early symptom. The factors that could
negatively influence the survival of patients with periam-
pullary cancer are positive resection margins,2,7,10–14
lymph node metastases,6,7,11,12,14–18 tumor size,12,14,19
blood vessel invasion,12,15 and poor tumor differentia-
tion.7,11,20 Perineural growth is an important prognostic
factor in several other types of cancer, eg, prostate,21
salivary gland,22 gastric,23 lung,24 and breast.25 Only a
limited number of studies analyzed perineural growth as a
prognostic factor in periampullary tumors.12,20,26–38 How-
ever, to our knowledge, no studies could be found that
concurrently analyzed perineural growth and tumor local-
ization as prognostic variables in a multivariate analysis.
This is relevant because in the preoperative workup pa-
tients are informed about their prognosis based on tumor
localization. For instance, patients with an ampullary car-
cinoma are told that they have a better prognosis than
patients with carcinoma of the pancreatic head. Addition-
ally, studies in which the effect of any (neo)adjuvant
treatment is analyzed should stratify patients based on
important prognostic or predictive variables.
In this study we tested the hypothesis that, analogous
to other types of cancer, perineural invasion is an impor-
tant prognostic variable in periampullary carcinomas. To
this end, we analyzed various clinicopathological vari-
ables, including, but not limited to, the site of origin of the
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tumor, lymph node status, resection margin, angioinva-
sion, and perineural growth.
PATIENTS AND METHODS
Between January 1989 and December 2006, 270 pa-
tients with a tumor of the periampullary region underwent
surgical treatment at our center. Patient data were entered in
a prospectively collected database. Preoperative workup con-
sisted of computed tomography scan of the abdomen and
thorax, and endoscopic retrograde cholangiopancreatography
with stent placement in jaundiced patients. Detection of liver
metastases or encasement of the superior mesenteric artery or
celiac axis was considered as a contraindication for pancre-
aticoduodenectomy. Visible tumors of the ampulla and duo-
denum were routinely biopsied during ERCP. Biopsy of
pancreatic head masses was not routinely performed because
a negative result of the biopsy does not preclude a surgical
procedure. Since 1995 diagnostic laparoscopy has been per-
formed in patients with pancreatic head tumors. This has only
been done in patients in whom a single or double bypass was
not indicated on clinical grounds in case tumors were not
resectable. Patients were scheduled for resection if during
laparoscopy no liver or peritoneal metastases were found.
During laparotomy, lymph nodes around the celiac
trunk and below the left renal vein between the aorta and
caval vein (numbers 9, 16, and 14, 15, respectively39) were
sent for frozen section, and if any of these were positive, the
patient was considered incurable and a double bypass con-
sisting of hepaticojejunostomy and gastrojejunostomy was
performed. Invasion of the portal or superior mesenteric vein
was not regarded as a contraindication for resection. In those
cases a venous reconstruction was performed using either
saphenous vein or umbilical vein.40 All patients who under-
went a resection received octreotide 3 times daily 0.1 mg
subcutaneously (Sandostatine, Novartis, Arnhem, The Neth-
erlands) from the day of operation until 2 weeks thereafter.
Several peri- and postoperative variables of the patients
were recorded: American Society of Anesthesiologists (ASA)
score,41 venous reconstruction, total blood loss, number of
blood transfusions needed intraoperatively or within the first
48 hours postoperatively, postoperative complications, length
of hospital stay, length of stay in the intensive care unit,
number of reoperations, number of percutaneous reinterven-
tions, and 30-day mortality. Postoperative complications
were classified as general complications (pulmonary or uri-
nary tract infection necessitating antibiotic treatment, drain-
age of wound abscess, deep vein thrombosis or pulmonary
embolism) or procedure-related complications such as leak-
age of biliary, pancreatic or enteric anastomoses, intra-ab-
dominal abscess or infected ascites (necessitating drainage),
or bleeding for which a reoperation was performed.
For this study all pathology specimens were reviewed
by one pathologist (ASHG) to confirm the diagnosis, lymph
node status, resection margins, the presence of perineural
growth, and angioinvasion. Tumors were reclassified accord-
ing to the most recent Tumor Node Metastasis (TNM) clas-
sification.42
All patients had a regular follow-up schedule consisting
of 3-monthly visits during the first 2 years after surgery and
6-monthly thereafter. Routine radiologic examinations were
not performed. Investigations like ultrasound, pulmonary
x-rays, or computed tomography scans were performed
whenever local recurrence or metastases were suspected. In
patients with recurrences palliative treatment, which could
include gemcitabin, was started. Depending on patients’ pref-
erence, follow-up could be stopped 5 years after surgery. In
those patients, general practitioners were contacted for defi-
nite long-term follow-up.
Survival analysis was performed using the Kaplan-
Meier method with the log rank test for comparisons. To
perform a more reliable analysis on the effect of the clinico-
pathological characteristics, patients who died within 30 days
after the operation were excluded from the long-term survival
analysis. Variables with a significant (P  0.1) effect in the
univariate analysis were included in the multivariate analysis,
using the Cox proportional hazard model.
RESULTS
Surgery for a periampullary tumor was performed in
270 patients; 163 (60%) patients were male and 107 patients
(40%) were female. The median age at the time of operation
was 60 years (range 11–80). A diagnostic laparoscopy was
performed in 116 patients (43%). An exploratory laparotomy
was then performed in 251 patients (92%). The total resect-
ability rate was 176 of 270 (65%) patients, of whom 155
(57%) underwent a pylorus-preserving and 21 (8%) a classic
pancreaticoduodenectomy (Whipple procedure). If the tumor
was not resectable during laparotomy, palliative bypass sur-
gery was performed. In 32 patients (12%) a double bypass
(hepaticojejunostomy and gastroenterostomy) was per-
formed, and 38 patients (14%) underwent a single bypass
(hepaticojejunostomy or gastroenterostomy).
The 30-day mortality rate was 4% (n  7) in the 176
patients who underwent a resection. The median intensive
care unit stay was 1 day (range 0–73) and median total
hospital stay was 24 days (range 9–131). Sixty-eight percent
of the 176 patients (n  119) did not require a blood
transfusion during or in the first 2 postoperative days. Nine
patients (5.1%) received 1 blood transfusion, 19 patients
(10.8%) received 2 blood transfusions, and the remaining
29 patients (16.5%) received 2 blood transfusions. In 26
patients (14.8%) a second laparotomy was necessary. In 16
patients (9.1%) a postoperative complication had to be
solved with a percutaneous intervention. In the patients
who underwent a resection, 29.5% (n  52) had one or
more general complications, and 34.1% (n  60) had a
procedure-related complication.
In 55 of the 176 patients who underwent pancreati-
coduodenectomy, various diagnoses other than periampullary
carcinoma were found on histologic examination; dysplasia
in 6% (n  11), neuroendocrine tumors in 6% (n  10), rare
malignant tumors in 4% (n 7), and benign disorders in 15%
(n  27). The diagnosis in the 121 patients (69%) who had a
periampullary carcinoma was pancreatic head carcinoma
(n  51, 42%), ampulla of Vater carcinoma (n  30, 25%),
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duodenum carcinoma (n  21, 17%), or distal bile duct
carcinoma (n  19, 16%).
Further analysis was done on the data from the 121
patients who underwent a resection for periampullary cancer
(pancreatic head, ampulla of Vater, distal bile duct, or duo-
denal carcinoma). Patient characteristics and more detailed
pathologic findings of this patient group are listed in Table 1.
Angioinvasion was found in 29% (n 35) of the patients and
perineural growth (Fig. 1) in 49% (n  59) of the cases.
Perineural growth was more frequently encountered in carci-
nomas of the pancreatic head (73%) than in carcinomas of the
ampulla of Vater (23%), distal bile duct (37%), and duode-
num (38%).
The median survival of all patients who underwent
pancreaticoduodenectomy for periampullary cancer was 29.1
months with an overall 5-year survival of 31.8%. In patients
with nonresectable tumors the median survival was 4.6
months, with no survivors after 24 months. If a microscopic
free resection margin (R0) could be obtained, the 5-year
overall survival was 38.5% and the median survival was 38.9
months. The median time of survival was 17.5 months, with
hardly any survivors beyond 36 months in patients with a R1
resection (Fig. 2). Survival in patients with R2 resections was
not different from patients who did not undergo pancreati-
coduodenectomy.
















Age (median) 63.3 65.6 61.9 57.5 63.1
Range (11–80) (46–76) (38–75) (18–80) (11–80)
Sex
Male 26 13 14 17 70
Female 25 17 5 4 51
T stage
1 5 10 5 2 22
2 20 14 3 6 43
3 26 5 11 8 50
4 0 1 0 5 6
N stage
0 16 16 15 9 56
1 35 14 4 12 65
Angioinvasion
Yes 20 7 2 6 35
No 31 23 17 15 86
Perineural
growth
Yes 37 7 7 8 59
No 14 23 12 13 62
SMV/PV
invasion
Yes 15 0 1 3 19
No 36 30 18 18 102
Resection
margin
R0 30 29 18 17 94
R1 14 0 1 3 18
R2 7 1 0 1 9
SMV indicates superior mesenteric vein; PV, portal vein.
FIGURE 1. Perineural growth: glandular structures of the ad-
enocarcinoma (asterisks) are present within the perineurium
of a nerve (arrow).
FIGURE 2. Survival rate for patients with periampullary carci-
noma and R0, R1, R2 resection, or no resection.
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Overall 3- and 5-year survival rates of patients stratified
according to the site of origin of the 4 tumor types in the
periampullary region are 26.1% and 17.9% (pancreatic head),
43.6% and 35.2% (ampulla of Vater), 73.7% and 53.6%
(distal bile duct), and 71.1% and 44.4% in duodenal carci-
noma, respectively. The corresponding median survival times
are 15.0 months (pancreatic head), 31.9 months (ampulla of
Vater), 102.0 months (distal bile duct), and 44.4 months
(duodenum).
In the combined group of patients with periampullary
cancer the presence of perineural growth was a significant
adverse risk factor. Patients having tumors with perineural
growth had a median survival of 17.3 months compared
with 64.4 months in the group without perineural growth
(P  0.002). In the patients with perineural growth there
were no 5-year survivors, which is in contrast to the 50.3%
5-year survival in the patients without perineural growth
(Fig. 3). In Figure 4 it can be seen that a 5-years survival of
more than 50% can be obtained in patients with nonpancre-
atic head carcinomas without perineural invasion. In contrast,
patients with nonpancreatic head carcinomas, in whom the
tumors show perineural invasion, have a comparable low
survival as patients with pancreatic head carcinoma with or
without perineural growth.
In the univariate analysis the following variables were
analyzed: T-status (T1 and T2 versus T3 and T4), N-status
(node positive versus node negative), tumor localization,
number of blood transfusions given (no transfusions versus
one or more transfusions), perineural growth (present versus
absent), angioinvasion (present versus absent), portal or su-
perior mesenteric vein reconstruction (yes versus no) and
resection margin (radical versus nonradical resection). Only
N status, perineural growth, angioinvasion, and resection
margin were significant prognostic variables in the univariate
analysis. Of note, median survival of patients with a venous
reconstruction because of tumor adherence to the portal or
superior mesenteric vein (18.1 months) was not significantly
different from those without this procedure (34.1 months,
P  0.14).
The multivariate analysis (Table 2) shows that perineu-
ral growth is the most important independent risk factor for
survival (RR 2.90). Other independent risk factors were the
resection margin, lymph node status, and the presence of
angioinvasion. Tumor localization proved not to be a signif-
icant risk factor (P  0.095); the P values of the individual
tumor localizations were not corrected for multiple compar-
isons and thus the P value of 0.02 (ampulla) should be
ignored.
DISCUSSION
In the present study we found that perineural invasion
is a more important prognostic factor than the primary site of
FIGURE 3. Survival rate after resection in patients with peri-
ampullary carcinoma with (perineural ) or without (peri-
neural ) perineural growth.
FIGURE 4. Survival rates in patients with resected periampul-
lary carcinoma. Other diagnosis   ampulla of Vater, distal
bile duct or duodenum carcinoma without perineural inva-
sion. Pancreas   pancreatic head carcinoma without peri-
neural invasion. Pancreas   pancreatic head carcinoma
with perineural invasion. Other diagnoses   ampulla of
Vater, distale bile duct, or duodenal carcinoma with perineu-
ral invasion.
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the periampullary carcinomas. Generally, pancreatic head
carcinoma is considered to have a worse prognosis compared
with the other periampullary carcinomas.2–4,7–9 However, it
might very well be that information, based on averages
obtained from a specific population (eg, patients with ampulla
of Vater cancer versus patients with pancreatic head cancer)
does not apply to the individual patient. Our data showed that
perineural growth is of paramount importance for the prog-
nosis of the individual patient. For instance, patients with a
pancreatic head carcinoma without perineural growth could
obtain a 5-year survival of around 30%, which is in contrast
to a 5-year survival of only 10% in patients with carcinomas
of the other periampullary sites, presumed to have a better
prognosis, with perineural growth. This difference is impor-
tant in the “personalized medicine” approach because a pa-
tient is more interested in his particular prognosis than in an
average prognosis of a patient group. Our data, however, are
not in contrast to several other series reporting on prognosis
of patients with periampullary carcinomas. We also con-
firmed the generally worse prognosis in the patient group
with pancreatic head carcinoma compared with patient
groups with the other periampullary carcinomas. This is
probably associated with the fact that perineural invasion is as
high as 73% in pancreatic head carcinomas and only 23% to
38% in the other periampullary carcinomas.
Table 3 shows the studies in which perineural growth
was included as a risk factor in periampullary tumors. These
studies, however, either restricted their analysis to pancreatic
head cancer or analyzed only a limited number of patients. To
the best of our knowledge no published study that addressed
perineural growth as an independent risk factor in patients
with all 4 types of periampullary cancer treated with a
pancreaticoduodenectomy is available. The current study
shows that perineural growth is an important clinicopatho-
logical factor in a relatively large group of 121 patients with
resected periampullary tumors.
Perineural growth is a phenomenon in which cancer
cells grow in close apposition to nerves. It can be encountered
in various tumor types, including head and neck cancer,22
prostate21 and pancreas carcinoma, and is, in general, asso-
ciated with a worse prognosis compared with tumors without
perineural growth. Originally, the idea was that lymphatics in
nerves harbor cancer cells, but later on it was suggested that
nerves are the routes of lowest resistance and thereby form a
TABLE 2. Results of Multivariate Analysis Using Cox
Regression, Showing the Relative Risk and 95% Confidence
Interval (CI) Compared To the Reference Standard (1.00).





Free margin (R0) 1.00
Not-free margin (R1,2) 2.28 (1.19-4.36)






Localization of carcinoma 0.095
Duodenum 1.00
Distal bile duct 1.44 (0.52-3.94) 0.481
Ampulla of Vater 2.60 (1.16-5.80) 0.020
Pancreatic head 2.03 (0.92-4.45) 0.079
TABLE 3. Overview of Literature With Analysis of Perineural Growth as a Prognostic Factor for Survival in









Author, Year N UV MV N UV MV N UV MV N UV MV
Nagakawa, 199326 21  15 
Griffanti-Bartoli,199427 14   22  
Sperti, 199528 113  
Chan, 199529 20   29  
Nakao, 199630 129 
Takahashi, 199731 90  
Zerbi, 199832 27  
Bouvet, 200020 129  
Schwartz, 200134 49  
Okusaka, 200135 95 
Hirai, 200236 24  
Duffy, 200337 55  
Shimada, 200638 80  
Garcea, 200712 33   20  
No literature was found on the impact of perineural growth in patients with duodenal carcinoma.
N indicates the number of patients; MV, multivariate analysis; UV, univariate analysis;, significant impact on prognosis of the patient;, no significant
impact on prognosis.
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paved way for dissemination and spread of tumor cells.43
More recent studies revealed that the interaction of nerves
and tumor cells is more complex. In prostate cancer it was
shown that nerves provide a prosperous environment for
tumor growth by up-regulation of antiapoptotic pathways in
cancer cells.44 In this study it was found that prostate cancer
cells in the perineural space had a higher proliferation index
and a lower apoptotic index than tumor cells located distant
from nerves. In cocultures of dorsal root ganglia and pancre-
atic cancer cells the neuroepithelial interaction had beneficial
effects on the growth of both nerves and cancer cells.45 It was
suggested that the production of growth factors by the nerves
contributes to tumor progression. Overexpression of trans-
forming growth factor  in nerves combined with the pres-
ence of its receptor, epidermal growth factor receptor, in
pancreatic cancer cells provides a plausible explanation for
cancer progression by paracrine stimulation.46
More recently another mechanism was described; it
was found that the neurotrophic growth factor artemin and its
receptors are up-regulated in human pancreatic cancer spec-
imens.47 In vitro experiments revealed that artemin enhances
the invasive potential of pancreatic cancer cells but not their
proliferation rate.47 Other evidence of the possible reciprocal
stimulation of nerves and pancreatic cancer was obtained
from experiments that revealed that vascular endothelial
growth factor (VEGF) stimulates proliferation of pancreatic
cancers and cancer cell lines, despite the absence of VEGF
receptors.48 The authors supplied compelling evidence that
VEGF is able to exert this action by binding to neuropilins,
which are (co)receptors for VEGF and also stimulators of
axonal outgrowth and survivals.48,49 Up-regulation of neu-
ropilin-1 was associated with an increase in invasiveness
and metastatic behavior in various other gastrointestinal
cancers.50
Taken together, nerves and pancreatic cancer cells
interact by reciprocal stimulation via paracrine and autocrine
mechanisms and thereby contribute to cancer progression,
more aggressive behavior and its associated poor prognosis.
Another important finding in our study is that a venous
reconstruction of the portal or superior mesenteric vein (per-
formed in 16% of the patients) did not adversely affect the
prognosis. This finding is in agreement with the results
published by other authors.51–53 In one study real tumor
invasion into the portal or superior mesenteric vein was
associated with a significantly worse prognosis compared
with patients in whom the tumor was adherent to the vein but
the resection margin was negative.54
Our finding of a difference of the 5-year survival
between patients with R0 and R1 resections concurred with
the results of Raut et al.18 In their study 92% of the patients
with R1 resections had either preoperative or postoperative
(chemo)radiotherapy. This probably explains the comparable
survival in patients with R0 and R1 resection in their series as
compared with ours in which no prior postoperative (chemo)-
radiotherapy was given.
Recently Oettle et al described that gemcitabine given
postoperatively significantly delayed the development of re-
current disease after complete resection of pancreatic cancer
compared with observation only.55 However, this randomized
study used a randomization procedure with stratification for
resection status, T status (according to TNM classification42)
and nodal status, without mentioning perineural growth. In
our study we found perineural growth the most important
prognostic factor. We therefore recommend using perineural
growth as a stratification marker in future studies on prom-
ising chemotherapeutics. In conclusion, the results of this
study show that perineural growth is an important prognostic
factor in patients with periampullary adenocarcinomas.
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